Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Ani Pharmaceuticals (ANIP) Cash from Operations (2016 - 2026)

Ani Pharmaceuticals' Cash from Operations history spans 16 years, with the latest figure at 30367000.0 for Q4 2025.

On a quarterly basis, Cash from Operations rose 91.47% to 30367000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 185225000.0, a 189.34% increase, with the full-year FY2025 number at 185225000.0, up 189.34% from a year prior.
Cash from Operations hit 30367000.0 in Q4 2025 for Ani Pharmaceuticals, down from 44055000.0 in the prior quarter.
Over the last five years, Cash from Operations for ANIP hit a ceiling of 75812000.0 in Q2 2025 and a floor of 18942000.0 in Q1 2022.
Historically, Cash from Operations has averaged 17016000.0 across 5 years, with a median of 17841500.0 in 2024.
Biggest five-year swings in Cash from Operations: plummeted 4865.15% in 2022 and later surged 1116.82% in 2023.
Tracing ANIP's Cash from Operations over 5 years: stood at 12185000.0 in 2021, then skyrocketed by 63.89% to 4400000.0 in 2022, then surged by 1116.82% to 44740000.0 in 2023, then tumbled by 64.55% to 15860000.0 in 2024, then soared by 91.47% to 30367000.0 in 2025.
Business Quant data shows Cash from Operations for ANIP at 30367000.0 in Q4 2025, 44055000.0 in Q3 2025, and 75812000.0 in Q2 2025.